| 词条 | IBNtxA |
| 释义 |
| IUPAC_name = N-[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl]-3-iodobenzamide | image = IBNtxA_structure.png | width = 220 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = | ATC_prefix = none | ATC_suffix = | PubChem = 51003467 | ChemSpiderID = 26617995 | C=27 | H=29 | I=1 | N=2 | O=4 | molecular_weight = 572.434 g/mol | smiles = C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1NC(=O)C7=CC(=CC=C7)I)OC5=C(C=C4)O)O | StdInChI = 1S/C27H29IN2O4/c28-18-3-1-2-17(12-18)25(32)29-19-8-9-27(33)21-13-16-6-7-20(31)23-22(16)26(27,24(19)34-23)10-11-30(21)14-15-4-5-15/h1-3,6-7,12,15,19,21,24,31,33H,4-5,8-11,13-14H2,(H,29,32)/t19-,21-,24+,26+,27-/m1/s1 | StdInChIKey = FGAFDGWRFOJPRY-XGTKUTNFSA-N | synonyms = }}IBNtxA, or 3-iodobenzoyl naltrexamine, is an atypical opioid analgesic drug derived from naltrexone. In animal studies it produces potent analgesic effects that are blocked by levallorphan and so appear to be μ-opioid mediated, but it fails to produce constipation or respiratory depression, and is neither rewarding or aversive in conditioned place preference protocols. These unusual properties are thought to result from agonist action at a splice variant or heterodimer of the μ-opioid receptor, rather than at the classical full length form targeted by conventional opioid drugs.[1][2][3][4][5] References1. ^Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, Pintar J, Pan YX, Pasternak GW. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proceedings of the National Academy of Sciences USA. 2011 Dec 6;108(49):19778-83. {{PMID|22106286}} {{Opioidergics}}{{analgesic-stub}}2. ^{{cite journal |vauthors=Majumdar S, Subrath J, Le Rouzic V, Polikar L, Burgman M, Nagakura K, Ocampo J, Haselton N, Pasternak AR, Grinnell S, Pan YX, Pasternak GW |title=Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants |journal=J. Med. Chem. |volume=55 |issue=14 |pages=6352–62 |year=2012 |pmid=22734622 |pmc=3412067 |doi=10.1021/jm300305c |url=}} 3. ^{{cite journal |vauthors=Wieskopf JS, Pan YX, Marcovitz J, Tuttle AH, Majumdar S, Pidakala J, Pasternak GW, Mogil JS |title=Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene |journal=Pain |volume=155 |issue=10 |pages=2063–70 |year=2014 |pmid=25093831 |doi=10.1016/j.pain.2014.07.014 |pmc=4372857}} 4. ^{{cite journal |vauthors=Grinnell SG, Majumdar S, Narayan A, Le Rouzic V, Ansonoff M, Pintar JE, Pasternak GW |title=Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA |journal=J. Pharmacol. Exp. Ther. |volume=350 |issue=3 |pages=710–8 |year=2014 |pmid=24970924 |doi=10.1124/jpet.114.213199 |pmc=4152881}} 5. ^Keck TM, Uddin MM, Babenko E, Wu C, Moura-Letts G. Abuse Liability and Anti-Addiction Potential of the Atypical Mu Opioid Receptor Agonist IBNtxA. The FASEB Journal 31 (1 Supplement), 985.4-985.4, 2017 4 : Benzamides|Mu-opioid agonists|Phenols|Semisynthetic opioids |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。